Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Innoviva Inc (INVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,440,958
  • Shares Outstanding, K 101,262
  • Annual Sales, $ 261,000 K
  • Annual Income, $ 395,060 K
  • 60-Month Beta 1.70
  • Price/Sales 5.47
  • Price/Cash Flow 3.43
  • Price/Book 7.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Sell
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.42
  • Number of Estimates 1
  • High Estimate 0.42
  • Low Estimate 0.42
  • Prior Year 0.49
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.53 +6.21%
on 06/03/19
14.73 -2.44%
on 05/22/19
-0.23 (-1.58%)
since 05/17/19
3-Month
13.07 +9.95%
on 04/22/19
15.27 -5.89%
on 05/07/19
+0.19 (+1.34%)
since 03/18/19
52-Week
13.07 +9.95%
on 04/22/19
20.54 -30.04%
on 01/30/19
-0.12 (-0.83%)
since 06/18/18

Most Recent Stories

More News
Celgene (CELG) Hits 52-Week High, Can the Run Continue?

Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CELG : 97.47 (+0.17%)
INVA : 14.36 (+0.91%)
MITO : 12.85 (+4.81%)
NLNK : 1.60 (+4.58%)
5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon

Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.

CELG : 97.47 (+0.17%)
INVA : 14.36 (+0.91%)
BDSI : 4.35 (+0.46%)
UBX : 8.45 (-7.85%)
CBM : 43.66 (+1.06%)
Earnings Estimates Moving Higher for Innoviva (INVA): Time to Buy?

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

INVA : 14.36 (+0.91%)
New Strong Buy Stocks for May 15th

New Strong Buy Stocks for May 15th

INVA : 14.36 (+0.91%)
FET : 3.56 (+3.19%)
NDLS : 7.03 (+0.14%)
CLMT : 4.29 (-0.69%)
ASIX : 26.60 (+1.84%)
Market Trends Toward New Normal in lululemon athletica inc, Innoviva, aTyr Pharma, and Vivopower International Plc -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of lululemon athletica inc....

LULU : 186.28 (+1.60%)
INVA : 14.36 (+0.91%)
VVPR : 1.06 (unch)
LIFE : 0.34 (-2.86%)
Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy...

INVA : 14.36 (+0.91%)
GSK : 40.08 (+0.38%)
Innoviva: 1Q Earnings Snapshot

BRISBANE, Calif. (AP) _ Innoviva Inc. (INVA) on Wednesday reported first-quarter profit of $33.8 million.

INVA : 14.36 (+0.91%)
Innoviva Reports First Quarter 2019 Financial Results

--Income before income taxes increased by 60% to $48.5 million in the first quarter of 2019, compared to the same quarter in 2018.

INVA : 14.36 (+0.91%)
Innoviva: 4Q Earnings Snapshot

BRISBANE, Calif. (AP) _ Innoviva Inc. (INVA) on Wednesday reported fourth-quarter net income of $263.8 million.

INVA : 14.36 (+0.91%)
Innoviva Reports Fourth Quarter 2018 Financial Results

--Income before income taxes increased 25% from the fourth quarter of 2017 to $73.1 million.

INVA : 14.36 (+0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade INVA with:

Business Summary

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance,...

See More

Key Turning Points

2nd Resistance Point 14.42
1st Resistance Point 14.33
Last Price 14.36
1st Support Level 14.04
2nd Support Level 13.84

See More

52-Week High 20.54
Fibonacci 61.8% 17.69
Fibonacci 50% 16.81
Fibonacci 38.2% 15.92
Last Price 14.36
52-Week Low 13.07

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar